拉米夫定联合卡托普利治疗慢性乙型肝炎肝纤维化的疗效分析

目的:研究联合使用抗病毒药物和血管紧张素拮抗剂治疗慢性乙型肝炎的抗肝纤维化疗效,探索疗效显著的治疗方案.方法:回顾性分析单纯护肝治疗、拉米夫定抗病毒、卡托普利降血压治疗及联合使用拉米夫定、卡托普利治疗至少1年的慢性乙型肝炎患者共166例的临床资料,通过比较使用不同治疗方案患者治疗前后肝纤维化血清标志物变化情况,评价不同治疗方案的抗肝纤维化疗效.结果与结论:使用不同方案的所有治疗组患者治疗前后,肝纤维化血清标志物水平差异均有统计学意义,而且联合治疗组差异具有显著统计学意义;Ridit分析显示各治疗组抗肝纤维化疗效由高到低依次是联合用药组、拉米夫定组、卡托普利组、单纯护肝组.

The anti-fibritic effect of combination treatment with lamivudine and captopril on patients with chronic hepatictis B

Objective:To study anti-fibrosis effect of combination treatment with lamivudine and captopril on patients with chronic hepatitis B (CHB). Methods: Clinical data of 166 cases of CHB patients who were divided into protecting liver group, lamivudine treatment group, captopril treatment group and combination treatment group with lamivudine and captopril. The change of serum fibrosis markers of CHB patients before and after treatment were determined. Results and Conclusions: All the levels of liver serum fibrosis markers before and after treatment changed siginificantly among 4 treatment groups, especially combination treatment group. Ridit analysis showed that combination treatment group provided greater anti-fibrosis efficacy than other groups in terms of efficacy rate.